Daniel B. Blatt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Daniel B. Blatt has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Ali Yalcindag
Hasbro Children’s Hospital, The Warren Alpert Medical School of Brown University, Providence, RI 02903, USA
1 shared publication April M Bobenchik
Division of Infectious Diseases, Departments of Pathology and Laboratory Medicine, Rhode Island Hospital and Warren Alpert Medical School of Brown University, Providence
1 shared publication- Ayelet Rosenthal
Division of Infectious Diseases, Ann & Robert H. Lurie Children’s Hospital of Chicago
1 shared publication - Caitlin L. McGrath
Department of Pediatrics, Division of Pediatric Infectious Diseases, University of Washington School of Medicine, Seattle, WA, USA
1 shared publication Catherine Murphy
Division of Infectious Diseases, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA
1 shared publicationDanielle M. Zerr
Department of Pediatrics, University of Washington, Seattle, WA, USA
1 shared publication
Latest Publications
- Open Access
- 14 November 2024
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 46 (1) , 3-26
SHEA practice update: infection prevention and control (IPC) in residential facilities for pediatric patients and their families
In 2011, the Society for Healthcare Epidemiology of America (SHEA) and Ronald McDonald House Charities® (RMHC®) established a formal collaboration to develop the first IPC guideline. Both organizations agreed that RMH programs staff and other organizations operating similar programs would benefit from a standardized approach. In 2023, the collaboration was re-established to revise and update the original IPC guideline. This SHEA Practice Update on “Infection Prevention and Control (IPC) in Residential Facilities for Pediatric Patients and Their Families” addresses preventing transmission of infectious agents in “home away from home” residential settings, of which the Ronald McDonald Houses (RMHs) serve as a prototype.
- 14 November 2024
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 46 (1) , 3-26
Open AccessSHEA practice update: infection prevention and control (IPC) in residential facilities for pediatric patients and their families
In 2011, the Society for Healthcare Epidemiology of America (SHEA) and Ronald McDonald House Charities® (RMHC®) established a formal collaboration to develop the first IPC guideline. Both organizations agreed that RMH programs staff and other organizations operating similar programs would benefit from a standardized approach. In 2023, the collaboration was re-established to revise and update the original IPC guideline. This SHEA Practice Update on “Infection Prevention and Control (IPC) in Residential Facilities for Pediatric Patients and Their Families” addresses preventing transmission of infectious agents in “home away from home” residential settings, of which the Ronald McDonald Houses (RMHs) serve as a prototype.
- 11 June 2019
- Published by Oxford University Press (OUP) in Journal of the Pediatric Infectious Diseases Society
- Vol. 9 (1) , 100-105
Cryptococcus albidus Fungemia in an Immunosuppressed Child: Case Report and Systematic Literature Review
Cryptococcus albidus, synonymous with Naganishia albida, rarely causes opportunistic infection in immunocompromised individuals. Its clinical features, particularly in children, are not well defined. Here, we report a case of C albidus fungemia in an immunosuppressed child; we also present results of a systematic review, for which we searched PubMed, Embase, and Web of Science using the keywords "cryptococcus" and "albidus." Our goal was to describe the spectrum of disease, diagnostic approaches, therapies, and outcomes. We identified 20 cases of invasive infection, only 2 of which involved children, and 7 cases of noninvasive infection. The reports originated in the Americas, Europe, and Asia. Of those with invasive infection, 16 (80%) patients had an underlying chronic disorder or had received immunosuppressive therapy, 8 (40%) had fungemia, and 6 (30%) had a central nervous system infection. The attributable case fatality rate was 40%. C albidus is an opportunistic yeast that can rarely cause life-threatening fungemia and central nervous system infection in individuals of any age, especially those who are immunocompromised.
- 11 June 2019
- Published by Oxford University Press (OUP) in Journal of the Pediatric Infectious Diseases Society
- Vol. 9 (1) , 100-105
Cryptococcus albidus Fungemia in an Immunosuppressed Child: Case Report and Systematic Literature Review
Cryptococcus albidus, synonymous with Naganishia albida, rarely causes opportunistic infection in immunocompromised individuals. Its clinical features, particularly in children, are not well defined. Here, we report a case of C albidus fungemia in an immunosuppressed child; we also present results of a systematic review, for which we searched PubMed, Embase, and Web of Science using the keywords "cryptococcus" and "albidus." Our goal was to describe the spectrum of disease, diagnostic approaches, therapies, and outcomes. We identified 20 cases of invasive infection, only 2 of which involved children, and 7 cases of noninvasive infection. The reports originated in the Americas, Europe, and Asia. Of those with invasive infection, 16 (80%) patients had an underlying chronic disorder or had received immunosuppressive therapy, 8 (40%) had fungemia, and 6 (30%) had a central nervous system infection. The attributable case fatality rate was 40%. C albidus is an opportunistic yeast that can rarely cause life-threatening fungemia and central nervous system infection in individuals of any age, especially those who are immunocompromised.